Short summary

The project aims to caracterize and subtype male breast cancer using the Prosigna PAM50 multigene test and immunohistochemical stainings. Correlation between molecular subtype found using PAM50 and immunohistochemical stainings will be examined as well as clinical outcome based on molecular subtype.

Rationale

Male breast cancer is a rare disease with approximately 35 newly diagnosed patients each year in Denmark. Male breast cancer is significantly less well caracterized than female breast cancer. In the latter years a greater molecular understanding of breast cancer has been achieved, and it has been proven that four distinct molecular subtypes of breast cancer have prognostic value. Several genomic tests have been developed. One of these is Nanostrings Prosigna PAM50 genesignature that analyzes mRNA expressionen of 50 genes. 

Description of the cohort

Men surgically treated for breastcancer at Odense Universityhospital in the time period 01.01.1997 - 31-12-2017 will be included in this study.

Data and biological material

Clinical and histological data including molecular subtype will be collected.

Collaborating researchers and departments

Department of Pathology, Odense University Hospital

• Consultant Anne Marie Bak Jylling

Department of Organ and Plastic Surgery, Breast Centre, Lillebaelt Hospital, Vejle

• Consultant Marianne Djernes Lautrup